natgillin/translations-raw huggingface dataset:
Thus full efficacy of linagliptin in combination with strong P-gp inducers might not be achieved, particularly if these are administered long-term.
Torej je mogoče, da polna učinkovitost linagliptina v kombiniranju z močnimi induktorji P-glikoproteina ne bo dosežena, zlasti pri dolgotrajni uporabi.
A limited amount of data suggests that the use of metformin in pregnant women is not associated with an increased risk of congenital malformations.
Manjše število podatkov o uporabi metformina pri nosečnicah ne kaže na povečano nevarnost kongenitalnih malformacij.
If you experience any of the signs of illness mentioned above, stop taking Jentadueto and call your doctor right away.
Če se pojavijo, katerikoli od zgoraj omenjenih znakov bolezni, zdravilo Jentadueto prenehajte jemati in takoj pokličite svojega zdravnika.
What Jentadueto is and what it is used for What you need to know before you take Jentadueto How to take Jentadueto
Kaj je zdravilo Jentadueto in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Jentadueto Kako jemati zdravilo Jentadueto Možni neželeni učinki
The only observed interaction between linagliptin and metformin was a reduction of body weight gain.
Edina opažena interakcija med linagliptinom in metforminom je bilo zmanjšanje prirasta telesne mase.
The study population included 1211 (17.4%) patients ≥ 75 years of age and 4348 (62.3%) patients with renal impairment.
Študijska populacija je vključevala 1211 (17,4 %) bolnikov, starih ≥ 75 let, in 4348 (62,3 %) bolnikov z ledvično okvaro.
If the patient plans to become pregnant, or if pregnancy occurs, treatment with Jentadueto should be discontinued and switched to insulin treatment as soon as possible in order to lower the risk of foetal malformations associated with abnormal blood glucose levels.
Če bolnica načrtuje nosečnost ali zanosi, je treba zdravljenje z zdravilom Jentadueto čim prej ukiniti in preiti na insulin, da bi zmanjšali nevarnost okvar ploda zaradi nenormalnih ravni glukoze v krvi.
The study included 3494 patients treated with linagliptin (5 mg) and 3485 patients treated with placebo.
V študiji je sodelovalo 3494 bolnikov, ki so se zdravili z linagliptinom (5 mg), in 3485 bolnikov, ki so se zdravili s placebom.
The prospective randomised (UKPDS) study has established the long-term benefit of intensive blood glucose control in type 2 diabetes.
V prospektivni randomizirani študiji (UKPDS) je bila dokazana dolgoročna korist intenzivnega urejanja ravni glukoze v krvi pri sladkorni bolezni tipa 2.
In case of suspected symptoms, the patient should stop taking metformin and seek immediate medical attention.
Ob sumu na simptome mora bolnik prenehati z jemanjem metformina in takoj poiskati zdravniško pomoč.
Talk to your doctor for further instruction.
Za več navodil se posvetujte z zdravnikom.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
Incidence Rate per 1000 PY*
število preiskovancev stopnja pojavnosti na 1000 BL*
Jentadueto with alcohol
Zdravilo Jentadueto skupaj z alkoholom
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Jentadueto therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Jentadueto, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
You should continue your diet during treatment with Jentadueto and take care that your carbohydrate intake is equally distributed over the day.
Med zdravljenjem z zdravilom Jentadueto morate nadaljevati z dieto in paziti, da boste vnos ogljikovih hidratov enakomerno porazdelili čez ves dan.
OUTER CARTON AND LABEL - HDPE BOTTLE (17 AND 18 APPLICABLE ONLY FOR CARTON)
PODATKI NA ZUNANJI IN STIČNI OVOJNINI KARTONSKA ŠKATLA IN NALEPKA - HDPE PLASTENKA (17 IN 18 PRIMERNO SAMO ZA KARTONSKO ŠKATLO)
With metformin there was no change in AUC, however mean peak serum concentration of metformin was decreased by 18% when administered with food.
AUC metformina se ni spremenila, toda srednja največja koncentracija metformina v serumu se je pri jemanju s hrano zmanjšala za 18 %.
Jentadueto should be taken twice daily with meals to reduce the gastrointestinal adverse reactions associated with metformin.
Zdravilo Jentadueto je treba jemati dvakrat na dan ob jedi, da bi zmanjšali neželene učinke na prebavila, povezane z metforminom.
The patient should be informed and more frequent blood glucose monitoring performed, especially at the beginning of treatment with such medicinal products.
Bolnika je treba o tem poučiti in zlasti na začetku zdravljenja s temi zdravili pogosteje spremljati njegovo raven glukoze v krvi.
The effect of Jentadueto on human fertility has not been studied.
Študij o učinku zdravila Jentadueto na plodnost pri človeku niso izvedli.
Lactic acidosis is a medical emergency and must be treated in a hospital.
Laktacidoza je urgentno zdravstveno stanje, ki ga je treba zdraviti v bolnišnici.
Linagliptin binds very effectively to DPP-4 in a reversible manner and thus leads to a sustained increase and a prolongation of active incretin levels.
Linagliptin se zelo učinkovito reverzibilno veže na DPP-4, česar posledica je enakomerno zvišanje ravni aktivnih inkretinov in podaljšanje njenega trajanja.
General Jentadueto should not be used in patients with type 1 diabetes.
Splošno Zdravila Jentadueto ne smemo uporabljati za zdravljenje bolnikov s sladkorno boleznijo tipa 1.
Older subjects (65 to 80 years, oldest patient was 78 years) had comparable plasma concentrations of linagliptin compared to younger subjects.
Starejši (65 do 80 let, najstarejši bolnik je imel 78 let) in mlajši preizkušanci so imeli primerljive plazemske koncentracije linagliptina.
Do not use this medicine if the package is damaged or shows signs of tampering.
Ne uporabljajte tega zdravila, če opazite poškodovano ovojnino ali znake odpiranja.
Long-term treatment with metformin has been associated with a decrease in vitamin B12 absorption which may very rarely result in clinically significant vitamin B12 deficiency (e.g. megaloblastic anaemia).
Dolgotrajno zdravljenje z metforminom so povezovali z zmanjšano absorpcijo vitamina B12, kar lahko zelo redko privede do klinično pomembnega pomanjkanja tega vitamina (npr. megaloblastne anemije).
After an oral dose, the non-absorbed fraction recovered in faeces was 20-30%.
Po peroralnem odmerku znaša neabsorbirani delež, ki se pojavi v blatu, od 20 do 30 %.
This medicine can be used alone or with certain other medicines for diabetes like sulphonylureas, empagliflozin, or insulin.
To zdravilo lahko uporabljate samostojno ali hkrati z nekaterimi drugimi zdravili za sladkorno bolezen, na primer s sulfonilsečninami, empagliflozinom ali insulinom.
Body weight did not differ significantly between the groups.
Telesna masa se med skupinami ni pomembno razlikovala.
After an oral dose of metformin, Tmax is reached in 2.5 hours.
Po peroralni uporabi doseže metformin Tmax v 2,5 ure.
Metformin hydrochloride increases the transport capacity of all types of membrane glucose transporters (GLUTs) known to date.
Metforminijev klorid poveča sposobnost prenosa vseh doslej znanih membranskih prenašalcev glukoze (GLUT).
If you encounter blistering of the skin it may be a sign for a condition called bullous pemphigoid.
Če se pojavi mehurjavost kože, je to morda lahko znak obolenja, imenovanega bulozni pemfigoid.
You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dosage of Jentadueto.
Morda boste morali pogosteje opravljati preiskave glukoze v krvi in delovanja ledvic, zdravnik pa bo morda moral prilagoditi odmerek zdravila Jentadueto.
Adverse reactions previously reported with one of the individual active substances may be potential adverse reactions with Jentadueto, even if not observed in clinical trials with this medicinal product.
Neželeni učinki, o katerih so pred tem poročali pri posameznih učinkovinah, so lahko potencialni neželeni učinki tudi pri zdravilu Jentadueto, četudi niso bili opaženi v kliničnih preskušanjih tega zdravila.
Other medicines and Jentadueto
Druga zdravila in zdravilo Jentadueto
Immune system disorders Hypersensitivity (e.g. bronchial hyperreactivity)
Bolezni imunskega sistema preobčutljivost (npr. bronhialna hiperreaktivnost)
Therefore, caution is advised when Jentadueto is used in combination with a sulphonylurea and/or insulin.
Zato svetujejo previdnost pri uporabi zdravila Jentadueto v kombinaciji s sulfonilsečnino in/ali insulinom.
Diagnostic laboratory findings are decreased blood pH (<7.35), increased plasma lactate levels (>5 mmol/l) and an increased anion gap and lactate/pyruvate ratio.
Diagnostični laboratorijski izvidi so zmanjšan pH krvi (< 7,35), zvišane ravni laktata v plazmi (> 5 mmol/l) in povečana anionska vrzel ter razmerje laktat/piruvat.
Your doctor may prescribe this medicine together with another oral anti-diabetic medicine or insulin.
Zdravnik vam lahko to zdravilo predpiše hkrati z drugim antidiabetikom ali insulinom.
Metformin hydrochloride may act via 3 mechanisms:
Metforminijev klorid lahko deluje na tri načine:
What you need to know before you take Jentadueto Do not take Jentadueto - if you are allergic to linagliptin or metformin or any of the other ingredients of this medicine
Kaj morate vedeti, preden boste vzeli zdravilo Jentadueto Ne jemljite zdravila Jentadueto - če ste alergični na linagliptin ali metformin ali katero koli sestavino tega zdravila (navedeno v poglavju 6),
Elderly Caution should be exercised when treating patients 80 years and older (see section 4.2).
Starejši Pri zdravljenju bolnikov, starih 80 let in več, je potrebna previdnost (glejte poglavje 4.2).
83% of patients were taking metformin in combination with insulin in this trial.
V tej študiji je 83 % bolnikov jemalo metformin v kombinaciji z insulinom.
Evaluation should include serum electrolytes and ketones, blood glucose and, if indicated, blood pH, lactate, pyruvate, and metformin levels.
Ocena mora zajeti raven elektrolitov in ketonov v serumu, glukoze v krvi in, če je indicirano, pH krvi ter ravni laktata, piruvata in metformina.
No clinically relevant effect of Cmax and Tmax changes is expected; therefore linagliptin may be administered with or without food.
Klinično pomembnih posledic sprememb vrednosti Cmax in Tmax ni pričakovati, zato lahko bolniki jemljejo linagliptin s hrano ali brez nje.
The most effective method to remove lactate and metformin hydrochloride is haemodialysis.
Najučinkovitejša metoda odstranjevanja laktata in metforminijevega klorida je hemodializa.
In vitro assessment of interactions
Ocena medsebojnega delovanja in vitro
• in patients already being treated with the combination of linagliptin and metformin as separate tablets.
• pri bolnikih, ki se že zdravijo s kombinacijo linagliptina in metformina v ločenih tabletah.
Based on these studies there is no concern for carcinogenicity in humans.
Podatki študij kažejo, da ni tveganja za karcinogenost pri človeku.
Due to the metformin component, Jentadueto may cause a very rare, but very serious complication called lactic acidosis, particularly if your kidneys are not working properly.
Zaradi metformina lahko zdravilo Jentadueto povzroči zelo redek, a zelo resen neželeni učinek, imenovan laktacidoza, zlasti če ledvice ne delujejo pravilno.
Results were consistent for patients treated with or without metformin.
Rezultati so bili enaki pri bolnikih, ki so bili ali niso bili zdravljeni z metforminom.
It is not an inducer of CYP isozymes.
Ni induktor izocimov CYP.
A dose reduction of the sulphonylurea or insulin may be considered (see section 4.2).
Presoditi je treba o zmanjšanju odmerka sulfonilsečnine ali insulina (glejte poglavje 4.2).
Therefore, it is considered unlikely that linagliptin affects reproduction at therapeutic exposures in humans.
Zato ni verjetno, da bi linagliptin pri izpostavljenosti terapevtskim odmerkom vplival na reprodukcijo pri človeku.
Because glibenclamide is primarily metabolised by CYP2C9, these data also support the conclusion that linagliptin is not a CYP2C9 inhibitor.
Ker glibenklamid primarno presnavlja CYP2C9, ta izsledek potrjuje, da linagliptin ne zavira CYP2C9.
Placebo Linagliptin 5 mg Once
Placebo Linagliptin 5 mg enkrat na dan
Continue to take Jentadueto as long as your doctor prescribes it so you can continue to help control your blood sugar.
Zdravilo Jentadueto jemljite tako dolgo, kot vam bo vaš zdravnik predpisal, da boste dodatno uravnavali svoj krvni sladkor.
It does not stimulate insulin secretion and therefore does not produce hypoglycaemia.
Ne stimulira izločanja insulina in tako ne povzroči hipoglikemije.
C] linagliptin dose to healthy subjects, approximately 85% of the administered radioactivity was eliminated in faeces (80%) or urine (5%) within 4 days of dosing.
C]linagliptina se je pri zdravih preizkušancih približno 85 % radioaktivnosti izločilo z blatom (80 %) ali s sečem (5 %) v 4 dneh po dajanju.
The renal composite endpoint was defined as renal death or sustained end stage renal disease or sustained decrease of 40% or more in eGFR.
Sestavljeni ledvični izid je bil opredeljen kot ledvična smrt ali trajna končna ledvična odpoved ali trajno znižanje oGFR za 40 % ali več.
There was no increased risk in hospitalization for heart failure which was an additional adjudicated endpoint observed compared to standard of care without linagliptin in patients with type 2 diabetes (table 4).
Ni bilo povečanega tveganja za hospitalizacijo zaradi srčnega popuščanja, kar je bil dodatni ugotovljeni izid v primerjavi s standardno terapijo brez jemanja linagliptina pri bolnikih s sladkorno boleznijo tipa 2 (preglednica 4).
However, patients should be alerted to the risk of hypoglycaemia when Jentadueto is used in combination with other antidiabetic medicinal products known to cause hypoglycaemia (e.g. sulphonylureas).
Bolnike je treba opozoriti na nevarnost hipoglikemije pri uporabi zdravila Jentadueto v kombinaciji z drugimi antidiabetiki, za katere je znano, da povzročajo hipoglikemijo (npr. sulfonilsečnine).
• Disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic disease) such as: decompensated heart failure, respiratory failure, recent myocardial infarction,
• bolezni, ki lahko povzročijo tkivno hipoksijo (predvsem akutne bolezni ali poslabšanje kroničnih bolezni), kot so: dekompenzirano srčno popuščanje, odpoved dihal, nedavni miokardni infarkt, šok.
The intra-subject and inter-subject coefficients of variation for linagliptin AUC were small (12.6% and 28.5%, respectively).
Koeficienti variacije AUC linagliptina med vsemi preizkušanci in pri posameznem so bili majhni (12,6 % oziroma 28,5 %).
In case of dehydration (severe diarrhoea or vomiting, fever or reduced fluid intake), metformin should be temporarily discontinued and contact with a health care professional is recommended.
V primeru dehidracije (huda driska ali bruhanje, zvišana telesna temperatura ali zmanjšan vnos tekočine) je treba jemanje metformina začasno prekiniti; priporoča se posvet z zdravstvenim delavcem.
However, taking Jentadueto in combination with medicines called sulphonylureas or with insulin can cause too low blood sugar level (hypoglycaemia), which may affect your ability to drive and use machines or work without safe foothold.
Toda jemanje zdravila Jentadueto v kombinaciji z zdravili, ki jih imenujemo sulfonilsečnine ali z insulinom, lahko povzroči premočno znižanje ravni krvnega sladkorja (hipoglikemijo), ki lahko zmanjša vašo sposobnost za vožnjo in uporabo strojev ali delo brez varne opore na tleh.
- Metformin belongs to a class of medicines called biguanides.
- Metformin je zdravilna učinkovina iz skupine zdravil, poimenovane bigvanidi.
Your doctor may prescribe a medicine to treat your allergic reaction and a different medicine for your diabetes.
Zdravnik vam bo predpisal zdravilo za alergijsko reakcijo in izbral drugo zdravilo za sladkorno bolezen.
GLP-1 and GIP increase insulin biosynthesis and secretion from pancreatic beta cells in the presence of normal and elevated blood glucose levels.
GLP-1 in GIP povečata biosintezo in izločanje insulina iz celic beta trebušne slinavke, in sicer pri normalni in zvišani ravni glukoze v krvi.
The unbound concentrations, which are usually less than 1% at the therapeutic dose of linagliptin, were increased 4-5-fold after co-administration with ritonavir.
Nevezane koncentracije, ki so običajno pri terapevtskem odmerjanju linagliptina manjše od 1 %, so se povečale za 4- do 5-krat pri sočasnem dajanju z ritonavirjem.
The incidence of hypoglycaemia in the linagliptin group (7.5%) was significantly lower than that in the glimepiride group (36.1%).
Pojavnost hipoglikemije je bila v skupini, ki je jemala linagliptin (7,5 %), pomembno manjša kot v tisti, ki je jemala glimepirid (36,1 %).
Metformin is contraindicated in patients with GFR<30 ml/min and should be temporarily discontinued in the presence of conditions that alter renal function, see section 4.3).
Metformin je kontraindiciran pri bolnikih z GFR< 30 ml/min in ga je treba začasno ukiniti, če se pojavijo stanja, ki spremenijo delovanje ledvic, glejte poglavje 4.3.
After oral administration, metformin hydrochloride absorption is saturable and incomplete.
Po peroralni uporabi je absorpcija metforminijevega klorida saturabilna in nepopolna.
Medicinal products that can acutely impair renal function (such as antihypertensives, diuretics and NSAIDs) should be initiated with caution in metformin-treated patients.
Zdravila, ki lahko akutno okvarijo delovanje ledvic (kot so antihipertenzivi, diuretiki in nesteroidna protivnetna zdravila), je treba pri bolnikih, ki se zdravijo z metforminom, uvesti previdno.
Oral 2 year carcinogenicity studies in rats and mice revealed no evidence of carcinogenicity in rats or male mice.
Dveletne študije o karcinogenosti peroralnih odmerkov pri podganah in miših niso izkazale karcinogenega delovanja pri podganah ali mišjih samcih.
Renal clearance of metformin hydrochloride is > 400 ml/min, indicating that metformin hydrochloride is eliminated by glomerular filtration and tubular secretion.
Ledvični očistek metforminijevega klorida je > 400 ml/min, kar kaže, da se metforminijev klorid izloča z glomerulno filtracijo in tubulno sekrecijo.
Pharmacotherapeutic group: Drugs used in diabetes, combinations of oral blood glucose lowering drugs, ATC code: A10BD11
Farmakoterapevtska skupina: zdravila za zdravljenje diabetesa,kombinacije peroralnih antidiabetikov, oznaka ATC: A10BD11
Effects of linagliptin on other medicinal products
Učinki linagliptina na druga zdravila
For patients with acute and unstable heart failure, Jentadueto is contraindicated (see section 4.3).
Pri bolnikih z akutnim in nestabilnim srčnim popuščanjem je zdravilo Jentadueto kontraindicirano (glejte poglavje 4.3).
Linagliptin is a weak competitive and a weak to moderate mechanism-based inhibitor of CYP isozyme CYP3A4, but does not inhibit other CYP isozymes.
Linagliptin je šibak kompetitivni in glede na mehanizem delovanja šibak do zmeren zaviralec izocima CYP3A4, vendar drugih izocimov CYP ne zavira.
Alcohol intoxication is associated with an increased risk of lactic acidosis, particularly in cases of fasting, malnutrition or hepatic impairment.
Zastrupitev z alkoholom je povezana s povečanim tveganjem za laktacidozo, zlasti ob postenju, podhranjenosti ali okvari jeter.
Based on these results and in vivo drug interaction studies, linagliptin is considered unlikely to cause interactions with other P-gp substrates.
Na podlagi teh izsledkov in podatkov študij o medsebojnem delovanju in vivo ni verjetno, da bi linagliptin povzročal interakcije z drugimi substrati P-glikoproteina.
Other risk factors for lactic acidosis are excessive alcohol intake, hepatic impairment, inadequately controlled diabetes, ketosis, prolonged fasting and any conditions associated with hypoxia, as well as concomitant use of medicinal products that may cause lactic acidosis (see sections 4.3 and 4.5).
Drugi dejavniki tveganja za laktacidozo so pretirano uživanje alkohola, jetrna insuficienca, neustrezno nadzorovana sladkorna bolezen, ketoza, dolgotrajno postenje in vsa stanja, povezana s hipoksijo, ter sočasna uporaba zdravil, ki lahko povzročijo laktacidozo (glejte poglavji 4.3 in 4.5).
Renal clearance at steady-state was approximately 70 ml/min.
Ledvični očistek v stanju dinamičnega ravnovesja je bil približno 70 ml/min.
• in combination with other medicinal products for the treatment of diabetes, including insulin, in patients inadequately controlled with metformin and these medicinal products
• v kombinaciji z drugimi zdravili za zdravljenje sladkorne bolezni, vključno z insulinom, pri bolnikih z nezadostno urejeno boleznijo pri jemanju metformina v kombinaciji z drugimi zdravili;
During controlled clinical trials in healthy subjects, single doses of up to 600 mg linagliptin (equivalent to 120 times the recommended dose) were not associated with a dose dependent increase in adverse events.
V nadzorovanih kliničnih preskušanjih pri zdravih prostovoljcih enkratni odmerki do 600 mg linagliptina (ustreza 120-kratnemu priporočenemu odmerku) niso bili povezani z z odmerkom odvisnim povečanjem neželenih učinkov.
If you need to have an injection of a contrast medium that contains iodine into your bloodstream, for example in the context of an X-ray or scan, you must stop taking Jentadueto before or at the time of the injection.
Če vam bodo v krvni obtok injicirali kontrastno sredstvo, ki vsebuje jod, na primer zaradi rentgenskega ali drugega slikanja, morate pred časom injiciranja ali v tem času prenehati z jemanjem zdravila Jentadueto.
Stop taking Jentadueto for a short time if you have a condition that may be associated with dehydration (significant loss of body fluids) such as severe vomiting, diarrhoea, fever, exposure to heat or if you drink less fluid than normal.
Za kratek čas prenehajte jemati zdravilo Jentadueto, če imate stanje, ki je lahko povezano z dehidracijo (znatna izguba telesnih tekočin), kot je hudo bruhanje, driska, zvišana telesna temperatura, izpostavljenost vročini ali če pijete manj tekočine, kot običajno.
Single dose study: after single doses of metformin hydrochloride 500 mg, paediatric patients have shown a similar pharmacokinetic profile to that observed in healthy adults.
Študija z enkratnim odmerkom: po dajanju enkratnih odmerkov metforminijevega klorida 500 mg je bil farmakokinetični profil pri pediatričnih bolnikih podoben tistemu pri zdravih odraslih.
If you are overweight, continue your energy-restricted diet as instructed.
Če imate preveliko telesno maso, po navodilih nadaljujte z dieto z zmanjšano energijsko vrednostjo.
As metformin is excreted by the kidney, Jentadueto should be used with caution as age increases.
Ker se metformin izloča skozi ledvice, je treba zdravilo Jentadueto previdno uporabljati pri starejših bolnikih.
The clinical trials before marketing authorization have been performed up to a BMI equal to 40 kg/m
Klinična preskušanja, ki so jih opravili pred izdajo dovoljenja za promet, so zajela bolnike z indeksom telesne mase do 40 kg/m
Patients with heart failure are more at risk of hypoxia and renal impairment.
Pri bolnikih s srčnim popuščanjem obstaja večje tveganje za hipoksijo in ledvično okvaro.
Not all pack sizes may be marketed in your country.
Na trgu v vaši državi morda ni vseh navedenih pakiranj.
STOP taking Jentadueto and contact a doctor immediately if you notice any of the following serious side effects: - Severe and persistent pain in the abdomen (stomach area) which might reach through to your back, as well as nausea and vomiting, as it could be a sign of an inflamed pancreas
Takoj PRENEHAJTE jemati zdravilo Jentadueto in se posvetujte z zdravnikom, če opazite katerega od naslednjih resnih neželenih učinkov: - huda in persistentna trebušna bolečina (v predelu želodca), ki se lahko širi v hrbet; tudi slabost in bruhanje, ker so vsi lahko tudi znaki vnetja trebušne slinavke (pankreatitisa).
No dose adjustment
Brez prilagajanja odmerka.